hotspot -WSS

hotspot

author：fashion 2025-10-01 10:56:43 - browse：9615

An orange Flovent inhaler on a white background. -- health coverage from STAT — Adobe

As of Jan. 1, thousands of asthma patients in the U.S. will no longer be able to get refills for Flovent — one of the most popular inhalers in the U.S. for nearly 30 years.

Flovent’s manufacturer, GSK, has discontinued both versions of the product — Flovent HFA, an inhalation aerosol, and Flovent Diskus, an inhalation powder — and replaced each with what is known as an “authorized generic,” essentially the same product sold under a private label. Prasco, a U.S. drugmaker specializing in authorized generics, will distribute the new inhaler, sold as fluticasone.

The timing of the change is telling: Flovent’s price rose nearly 50% since 2014, according to GoodRx, leaving the drug vulnerable to the new Medicaid penalties going into effect as of this year for medications with price increases that outpace inflation. By discontinuing the brand-name inhaler but continuing to earn money from the authorized generic, GSK will be able to avoid paying a penalty.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： What to expect as Trump is arraigned on his Jan 6. indictment

WSS

National panel will explore requiring free Covid tests

Fed up with FDA, ALS advocates consider a take

Micronoma's microbiome cancer diagnostic approach under fire

Senate bill would ban some hospital facility fees

Fed up with FDA, ALS advocates consider a take

No plane should take off without an EpiPen onboard

hotspot

hotspot

focus

Alkermes shareholders re

Micronoma's microbiome cancer diagnostic approach under fire

Sports medicine is finally prioritizing gender equality

People with substance use disorder deserve online privacy

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Listen: Biogen's situation, Wegovy's risks, & biotech insider trading

In Memoriam: Notable people who died in 2023

What happened to the House vote on health price transparency?

Activists slam private health insurers over coverage restrictions

House panel takes first step toward fixing drug shortages

focus

Fed up with FDA, ALS advocates consider a take

Assistant physicians can help address the primary care shortage

What the US credit downgrade means for the economy, your finances

Pence says 'crackpot lawyers' told Trump what he wanted to hear

Infectious disease expert Jeanne Marrazzo assumes Fauci role

‘Oppenheimer’ and the risks of AI in health care

focus

focus

entertainment

focus